Skip to main content
OpenTrials
Completed

NCT Number: NCT01636635

Effect of Age and Weight Loss on Inflammation and Iron Homeostasis

The purpose of this study is to evaluate the effect of aging and weight loss on iron status and immune response in obese women. Iron deficiency and immune impairment are two of the numerous complications of obesity. The central hypothesis is that obesity-induced inflammation causes lower iron status through decreased iron absorption and availability in young and older obese women. Furthermore, the investigators hypothesize that this can be corrected with weight loss in both young and older obese women.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

JM USDA Human Nutrition Research Center on Aging

Boston, Massachusetts, 02111, United States

About this study

Obese individuals have chronic inflammation, higher risk of iron deficiency, and impaired immune response. These are conditions seen also with aging, but it is unknown to what extent they may be further impacted by obesity in the elderly. With this study the investigators aim to establish the mechanism by which weight loss may reduce inflammation and enhance iron status in young and older obese adults through the peptide hormone hepcidin, which regulates iron homeostasis. The investigators also aim to identify a possible link between iron homeostasis and immune response through hepcidin, which has been implicated in T cell mediated immunity. The investigators hypothesize that obesity-induced inflammation causes dysregulation of hepcidin expression leading to lower iron status through decreased iron absorption and availability in young and older adults. Furthermore, the investigators hypothesize that hepcidin dysregulation, and thus iron status can be mitigated with weight loss in both young and older obese adults. This hypothesis will be tested in obese young and older women undergoing weight loss through calorie restriction. Change in iron status, inflammation, and hepcidin will be determined before and after weight loss. Further, the impact of inflammatory environment of obesity on peripheral blood mononuclear cell hepcidin, ferroportin, intracellular iron, and T cell function in young and older adults will be determined. This study will address two important public health problems, i.e. obesity and iron deficiency and will be an important step toward the identification of strategies to enhance health of obese young and older adults.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Enrolling patients in the Weight and Wellness Center (WWC) at Tufts Medical Center, part of their Tufts Employees, low calorie diet (LCD) or pre-surgical low calorie diet (PS-LCD) program, or enrolling at WWC as individual patients.
  • BMI in the range of 30 to 55 kg/m2.
  • Either ages 18-45 or >60.

Exclusion criteria

  • Pregnancy.
  • Weight reduction greater than or equal to 3% in the past 3 months.
  • Prior gastric restrictive surgery.
  • Weight loss medications within the 4 weeks prior to screening.
  • History of eating disorder.
  • Renal disease (serum creatinine >2mg/dl).
  • Hepatic disease, except for nonalcoholic steatohepatitis (NASH).
  • Celiac disease, or any kind of intestinal malabsorption disorders.
  • Gastrointestinal cancer.
  • Hereditary hemochromatosis, or any blood disorders.
  • Chronic infectious or inflammatory disease.
  • Use of immunosuppressants.
  • Severe iron deficiency anemia (hemoglobin<8 g/dl) or other conditions that would prevent them from discontinuing iron supplement use.
  • Unwilling to discontinue iron supplement intake. The dietary plan recommended by the WWC will include daily intake of iron that meets the iron RDA for the subject's gender and age group, therefore discontinuing iron supplement will not be harmful for the participants. Intake of other supplements will not be an exclusion criteria, as long as it stays constant throughout the study period.

Treatment and study plan

Calorie Restriction

Other

Intervention consists of a calorically restricted diet regime designed and administered at the Weight and Wellness Center at Tufts University

Primary outcomes

  1. Change in serum hepcidin

    Time frame: Baseline and 12-16 weeks

    The investigators will determine the change in hepcidin at baseline and after 12-16 weeks of calorie restriction.

  2. Change in inflammation (CRP, IL-6)

    Time frame: Baseline and 12-16 weeks

    The investigators will determine the change in inflammation at baseline and after 12-16 weeks of calorie restriction.

  3. Change in iron status

    Time frame: Baseline and 12-16 weeks

    The investigators will determine the change in iron status at baseline and after 12-16 weeks of calorie restriction.

Secondary outcomes

  1. Change in PBMC intracellular iron content

    Time frame: Baseline and 12-16 weeks

  2. Change in PBMC Hepcidin expression

    Time frame: Baseline and 12-16 weeks

  3. Change in PBMC ferroportin expression

    Time frame: Baseline and 12-16 weeks

  4. Change in PBMC subpopulations and proliferation

    Time frame: Baseline and 12-16 weeks

    After stimulation with ConA, PHA and anti-CD3/CD28

Sponsors and collaborators

Lead sponsor

Tufts University

Other

Registry information

Official study title

Effect of Age and Weight Loss on Obesity-related Inflammation and Iron Homeostasis in Women

Acronym: HEP

Important dates

Study start
2011
Primary completion
2013
Study completion
2013
First posted
Jul 10, 2012
Registry last updated
Nov 16, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.